RE:Roche Tecentriq + Avastin met primary endpoint- liver cancer" Genentech has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across different lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines, as well as studies in metastatic, adjuvant and neoadjuvant settings across various tumor types."
https://www.biospace.com/article/releases/genentech-s-tecentriq-plus-avastin-is-the-first-treatment-combination-to-reduce-the-risk-of-cancer-returning-in-people-with-certain-types-of-early-stage-liver-cancer-in-a-phase-iii-trial/